Abstract Library

#2287 Mitochondrial or Aerobic Glycolysis Oriented Metabolism May Define Pancreatic Neuroendocrine Tumors (PanNET) Resistance to mTOR-Targeting Therapies

Introduction: The mTOR inhibitor Everolimus is approved for the treatment of PanNET and no predictive biomarker is available. mTOR is a central node controlling mitochondrial and aerobic glycolytic metabolisms.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cros J, Bucau M, Raffenne J, Soukeur M, Dumont F,

Keywords: mTOR, everolimus, pancreatic NET, metabolism,

#1742 Nucleolin (NCL) Regulates Aerobic Glycolysis in Pancreatic Neuroendocrine Tumor (p-NET) BON-1 Cells

Introduction: NCL, a nucleolus localized protein and ribosomal RNA (rRNA) expression regulator, has been reported to function as an oncogene in several tumors. However, the expression and role of NCL in p-NET remains unclear.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Jin K, Yu X,

Keywords: pancreatic neuroendocrine tumors (p-NETs), Nucleolin (NCL), ribosomal RNA, ATP, aerobic glycolysis,

#1362 Targeting Tumor Metabolism in NETs: A Novel Mechanism of Action of the Somatostatin Analog Lanreotide

Introduction: One of the hallmarks of cancer is reprogramming of energy metabolism, characterized by a shift to aerobic glycolysis. This metabolic switch provides cancer cells appropriate conditions required for enhanced proliferation and survival. The effects of somatostatin on tumor metabolism had not been determined yet.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Wolf I

Authors: Wolf I, Hesin A, Rubinstein T, Rubinek T, Shabtay-Orbach A,

Keywords: metabolism, glucose,